Precigen (NASDAQ:PGEN) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Precigen (NASDAQ:PGEN - Free Report) in a research report released on Thursday,Benzinga reports. They currently have a $6.00 price target on the biotechnology company's stock, up from their previous price target of $4.00.

Separately, JMP Securities restated a "market outperform" rating and set a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, Precigen has an average rating of "Hold" and a consensus target price of $7.00.

Precigen Trading Up 18.4 %

Shares of PGEN traded up $0.21 during mid-day trading on Thursday, hitting $1.34. The company's stock had a trading volume of 4,362,294 shares, compared to its average volume of 2,281,475. Precigen has a 1-year low of $0.65 and a 1-year high of $1.93. The firm has a market capitalization of $391.86 million, a P/E ratio of -2.46 and a beta of 1.65. The firm has a 50-day simple moving average of $0.92 and a 200 day simple moving average of $1.06.

Hedge Funds Weigh In On Precigen

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Iridian Asset Management LLC CT increased its position in shares of Precigen by 82.5% in the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company's stock valued at $3,576,000 after buying an additional 1,706,815 shares in the last quarter. LexAurum Advisors LLC raised its position in Precigen by 151.9% during the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company's stock worth $775,000 after acquiring an additional 417,055 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company's stock valued at $3,075,000 after purchasing an additional 149,829 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Precigen by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company's stock valued at $1,869,000 after purchasing an additional 130,500 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Precigen by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company's stock worth $1,158,000 after purchasing an additional 127,467 shares in the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.